FIELD: medicine.
SUBSTANCE: present group of inventions refers to medicine, namely to oncology, and concerns application of (E)-1-(3',4'-dimethoxyphenyl) butadiene as an anticancer agent in experiment. That is ensured by exposing prostate carcinoma cells, ovarian carcinoma and pancreatic carcinoma to said cells.
EFFECT: such exposure provides the anti-tumour effect inducing in all said types of cancer, as well as prevention of metastasis due to action on adhesive molecules of selectins.
5 cl, 2 ex, 1 tbl, 3 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| CONTROL POINT INHIBITOR AND WHOLE-CELL MICROBACTERIA FOR USE IN TREATING ONCOLOGICAL DISEASE | 2014 |
|
RU2719934C2 |
| USE OF CD 151 ANTIBODIES FOR TREATING CANCER | 2007 |
|
RU2464041C2 |
| ONCOLYTIC VIRAL VECTORS AND USE THEREOF | 2017 |
|
RU2749050C2 |
| ANTICANCER TUMOR CISPLATIN COMPOSITION WITH 6-PHOSPHOGLUCONATE DEHYDROGENASE INHIBITOR | 2019 |
|
RU2693004C1 |
| COMBINATIONS | 2015 |
|
RU2715236C2 |
| METHODS OF TREATING CANCER, HAVING HEMIZYGOUS LOSS OF TP53 | 2016 |
|
RU2721953C2 |
| METHOD OF TREATING CANCER (VERSIONS) | 2006 |
|
RU2447889C2 |
| FUSED DLK1-Fc PROTEIN AND USING IT FOR METASTASES INHIBITION, POLYNUCLEOTIDE CODING PROTEIN, VECTOR, HOST CELL, METHOD FOR PRODUCING FUSED PROTEIN, COMPOSITION AND METHOD FOR METASTASES INHIBITION | 2010 |
|
RU2531756C2 |
| COMBINATION OF INHIBITOR FGFR AND INHIBITOR IGF1R | 2015 |
|
RU2715893C2 |
| PHARMACEUTICAL FORMULATION FOR METASTASIS PREVENTION AND INCREASING OF TUMOUR SENSITISATION TO CHEMOTHERAPEUTIC AGENTS | 2007 |
|
RU2328282C1 |
